Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrolife AB's Other Operating Expense for the
three
months ended in Jun. 2026 was kr50 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was kr5,546 Mil.
Vitrolife AB's quarterly Other Operating Expense
declined
from Dec. 2025 (kr5,372 Mil) to Mar. 2026 (kr51 Mil) and
declined
from Mar. 2026 (kr51 Mil) to Jun. 2026 (kr50 Mil).
Vitrolife AB's annual Other Operating Expense
increased
from Dec. 2023 (kr-5 Mil) to Dec. 2024 (kr-2 Mil) but then
declined
from Dec. 2024 (kr-2 Mil) to Dec. 2025 (kr-13 Mil).
Vitrolife AB Other Operating Expense Related Terms
Vitrolife AB Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5,546 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of kr5,546 Mil mean?
Vitrolife AB (CHIX:VITRS) has a Other Operating Expense of kr5,546 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Vitrolife AB and its competitors.
Is Vitrolife AB's Other Operating Expense too high?
Vitrolife AB's current Other Operating Expense is kr5,546 Mil. Overall, Vitrolife AB has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Other Operating Expense compare to ABT and SYK?
Vitrolife AB's Other Operating Expense of kr5,546 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Devices & Instruments company?
A good Other Operating Expense depends on the Medical Devices & Instruments industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Vitrolife AB and its competitors. Vitrolife AB's current Other Operating Expense is kr5,546 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (CHIX:VITRS) is currently considered Possible Value Trap. The stock's GF Value™ is kr145.13, compared to a current price of kr86.38 — trading 40.5% below its estimated fair value. The current Other Operating Expense is kr5,546 Mil. Vitrolife AB's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Other Operating Expense is kr5,546 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr86.38 is trading 40.5% below its estimated GF Value™ of kr145.13.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for CHIX:VITRS:
Other Operating Expense: kr5,546 Mil
GF Value™: kr145.13 vs. price of kr86.38 (40.5% below fair value)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
74GF Score
Get the complete analysis for CHIX:VITRS
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
